Skip to main content

Table 3 Summary of main effects of quercetin on allergic diseases (in vitro and in vivo studies)

From: Quercetin with the potential effect on allergic diseases

Diseases Dosage Cell/cell line Animal Quercetin’s effect References
Allergic asthma 0.1–25 µM 16HBE14o BALB/c Blocks airway epithelial cell IL-8 and MCP-1 expression by attenuating the signaling through a PI-3 kinase/Akt/NF-κB pathway
Inhibits chemokine expression
Inhibits allergen sensitization, induced monocyte chemoattractant protein (MCP)-1 expression, and airways hyperresponsiveness, in vivo
20 mg/kg Spinal cord-tracheal smooth muscle Male guinea pig Caused significant bronchodilation, both in vivo and in vitro [6]
30 mg/kg Bone marrow-derived mast cells BALB/c Decrease allergen-induced development of airway hyperresponsiveness, TH2 responses in the lung, lung eosinophilia, and goblet cell metaplasia [33]
Various dose
Min–max (5–20 mg/kg)
Eosonophil BALB/c Suppressive effects on eosinophil activation [34]
30 mg/kg Spleen-tracheal smooth muscle A/J mice Reduction of inflammatory cytokines production, tracheal rings relaxation and also reduction of the total number of cells in BALF and eosinophil peroxidase in lungs [35]
100 μM Human ASM cells A/J mice Attenuated PLC activity, decreased inositol phosphate synthesis, and decreased intracellular calcium responses to Gq-coupled agonists in vitro
Increase of airway resistance in vivo
Human ASM cells BALB/c Treat obstructive lung diseases such as asthma and chronic obstructive pulmonary disease [37]
Allergic rhinitis 20 mg/kg HNEpC BALB/c Inhibited nasal symptoms and increased TRX levels in nasal lavage fluids [47]
Atopic dermatitis 10 mg/ml Skin biopsies Hsd:ICR (CD-1) mice Prevented the formation of skin lesions abrogating the various biochemical processes that cause epithelial loss and skin damage [56]
  1. MCP monocyte chemoattractant protein, PLC phospholipase C, TRX thioredoxin, BALF bronchoalveolar lavage fluid